Please check your internet connection and try again.
# Hyoscine butylbromide (Buscopan)
## Overview
Hyoscine butylbromide is a quaternary ammonium antispasmodic agent. Unlike hyoscine hydrobromide, it does not cross the blood-brain barrier and therefore lacks central nervous system effects. It acts as a peripheral muscarinic receptor antagonist, reducing smooth muscle spasms in the gastrointestinal, biliary, and urinary tracts.
## Primary Indications
* Symptomatic relief of gastrointestinal and genitourinary smooth muscle spasms (e.g., irritable bowel syndrome, biliary colic, renal colic).
* Radiological diagnostic procedures to reduce GI motility (off-label/protocol-dependent).
## Adult Dosing
* **Oral:** 10–20 mg three to four times daily. Maximum daily dose: 80–100 mg.
* **IV/IM/SC:** 20 mg as a single dose; may repeat after 30 minutes if necessary. Maximum daily dose: 100 mg.
## Pediatric Dosing
* **6–12 years:** 10 mg (one tablet) three times daily.
* **Under 6 years:** Not recommended for routine use.
* *Note: Dosing is highly dependent on local institutional protocols; consult specific pediatric formularies (e.g., BNFc).*
## Dose Adjustments
* **Renal/Hepatic Impairment:** Use with caution. No standardized formal dose reduction guidelines exist, but lower starting doses are recommended due to potential for accumulation and anticholinergic side effects.
* **Elderly:** Use caution; monitor for increased risk of urinary retention and cognitive sensitivity despite limited BBB penetration.
## Contraindications
* Hypersensitivity to hyoscine butylbromide.
* Myasthenia gravis.
* Megacolon.
* Mechanical intestinal obstruction or paralytic ileus.
* Narrow-angle glaucoma.
* Prostatic hypertrophy with urinary retention.
* Tachycardia or unstable cardiac conditions.
## Adverse Effects
* **Common:** Dry mouth, tachycardia, blurred vision (mydriasis), constipation.
* **Serious:** Urinary retention, anaphylaxis/allergic reactions (more common with parenteral administration), paradoxical bradycardia (transiently, especially with IV administration).
## Key Drug Interactions
* **Anticholinergics:** Enhanced anticholinergic side effects (e.g., TCAs, antihistamines, antipsychotics).
* **Dopamine Antagonists:** May result in reduced GI motility effects if co-administered with prokinetics like metoclopramide or domperidone.
* **Tachycardia-inducing agents:** May exacerbate tachycardia if used with beta-adrenergic stimulants.
## Monitoring
* Monitor heart rate, especially after IV administration.
* Assess for relief of pain/spasm.
* Monitor for signs of urinary retention.
* Evaluate visual disturbances or confusion (rare).
## Clinical Pearls
* **Parenteral Caution:** IV administration may cause transient tachycardia; infuse slowly.
* **Onset:** Oral onset is approximately 60 minutes; IV onset is within minutes.
* **Systemic Absorption:** Poor systemic absorption following oral administration (low bioavailability), which contributes to its favorable safety profile compared to tertiary amines.
* **Patient Education:** Advise patients to notify a physician if they experience "halos" around lights (potential glaucoma) or difficulty urinating.
***
*Disclaimer: This information is for educational purposes only. Drug dosing, contraindications, and indications can change based on regional guidelines and institutional protocols. Always consult current local prescribing information, product monographs, or clinical pharmacists before administering or prescribing medication.*
